172 related articles for article (PubMed ID: 22289987)
21. Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level.
Di Maira G; Brustolon F; Bertacchini J; Tosoni K; Marmiroli S; Pinna LA; Ruzzene M
Oncogene; 2007 Oct; 26(48):6915-26. PubMed ID: 17486073
[TBL] [Abstract][Full Text] [Related]
22. Protein kinase CK2 subunits are positive regulators of AKT kinase.
Guerra B
Int J Oncol; 2006 Mar; 28(3):685-93. PubMed ID: 16465374
[TBL] [Abstract][Full Text] [Related]
23. Role of protein kinases CK1α and CK2 in multiple myeloma: regulation of pivotal survival and stress-managing pathways.
Manni S; Carrino M; Piazza F
J Hematol Oncol; 2017 Oct; 10(1):157. PubMed ID: 28969692
[TBL] [Abstract][Full Text] [Related]
24. Validation of protein kinase CK2 as oncological target.
Seeber S; Issinger OG; Holm T; Kristensen LP; Guerra B
Apoptosis; 2005 Aug; 10(4):875-85. PubMed ID: 16133877
[TBL] [Abstract][Full Text] [Related]
25. Tyrosine kinase oncogenes in normal hematopoiesis and hematological disease.
Scheijen B; Griffin JD
Oncogene; 2002 May; 21(21):3314-33. PubMed ID: 12032772
[TBL] [Abstract][Full Text] [Related]
26. CK2 signaling in androgen-dependent and -independent prostate cancer.
Wang G; Ahmad KA; Unger G; Slaton JW; Ahmed K
J Cell Biochem; 2006 Oct; 99(2):382-91. PubMed ID: 16598768
[TBL] [Abstract][Full Text] [Related]
27. Assessment of CK2 constitutive activity in cancer cells.
Ruzzene M; Di Maira G; Tosoni K; Pinna LA
Methods Enzymol; 2010; 484():495-514. PubMed ID: 21036247
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase CK2: structure, regulation and role in cellular decisions of life and death.
Litchfield DW
Biochem J; 2003 Jan; 369(Pt 1):1-15. PubMed ID: 12396231
[TBL] [Abstract][Full Text] [Related]
29. Protein kinase CK2 catalyzes tyrosine phosphorylation in mammalian cells.
Vilk G; Weber JE; Turowec JP; Duncan JS; Wu C; Derksen DR; Zien P; Sarno S; Donella-Deana A; Lajoie G; Pinna LA; Li SS; Litchfield DW
Cell Signal; 2008 Nov; 20(11):1942-51. PubMed ID: 18662771
[TBL] [Abstract][Full Text] [Related]
30. Importance of epigenetic changes in cancer etiology, pathogenesis, clinical profiling, and treatment: what can be learned from hematologic malignancies?
Vecchio L; Seke Etet PF; Kipanyula MJ; Krampera M; Nwabo Kamdje AH
Biochim Biophys Acta; 2013 Aug; 1836(1):90-104. PubMed ID: 23603458
[TBL] [Abstract][Full Text] [Related]
31. The casein kinase 2 inhibitor, CX-4945, as an anti-cancer drug in treatment of human hematological malignancies.
Chon HJ; Bae KJ; Lee Y; Kim J
Front Pharmacol; 2015; 6():70. PubMed ID: 25873900
[TBL] [Abstract][Full Text] [Related]
32. Targeting Protein Kinases in Blood Cancer: Focusing on CK1α and CK2.
Spinello Z; Fregnani A; Quotti Tubi L; Trentin L; Piazza F; Manni S
Int J Mol Sci; 2021 Apr; 22(7):. PubMed ID: 33918307
[TBL] [Abstract][Full Text] [Related]
33. Repressing the activity of protein kinase CK2 releases the brakes on mitochondria-mediated apoptosis in cancer cells.
Hanif IM; Pervaiz S
Curr Drug Targets; 2011 Jun; 12(6):902-8. PubMed ID: 21269261
[TBL] [Abstract][Full Text] [Related]
34. Protein Kinase CK2, a Potential Therapeutic Target in Carcinoma Management.
Lian H; Su M; Zhu Y; Zhou Y; Soomro SH; Fu H
Asian Pac J Cancer Prev; 2019 Jan; 20(1):23-32. PubMed ID: 30677865
[TBL] [Abstract][Full Text] [Related]
35. Protein kinase CK2 signal in neoplasia.
Tawfic S; Yu S; Wang H; Faust R; Davis A; Ahmed K
Histol Histopathol; 2001 Apr; 16(2):573-82. PubMed ID: 11332713
[TBL] [Abstract][Full Text] [Related]
36. Cellular signaling and epigenetic regulation of gene expression in leukemia.
Gowda C; Song C; Ding Y; Iyer S; Dhanyamraju PK; McGrath M; Bamme Y; Soliman M; Kane S; Payne JL; Dovat S
Adv Biol Regul; 2020 Jan; 75():100665. PubMed ID: 31623972
[TBL] [Abstract][Full Text] [Related]
37. Phosphatase of regenerating liver in hematopoietic stem cells and hematological malignancies.
Kobayashi M; Chen S; Gao R; Bai Y; Zhang ZY; Liu Y
Cell Cycle; 2014; 13(18):2827-35. PubMed ID: 25486470
[TBL] [Abstract][Full Text] [Related]
38. Targeting protein kinase CK2 and CDK4/6 pathways with a multi-kinase inhibitor ON108110 suppresses pro-survival signaling and growth in mantle cell lymphoma and T-acute lymphoblastic leukemia.
Padgaonkar A; Rechkoblit O; Vasquez-Del Carpio R; Pallela V; Venkata Subbaiah D; Cosenza SC; Baker SJ; Ramana Reddy MV; Aggarwal A; Reddy EP
Oncotarget; 2018 Dec; 9(102):37753-37765. PubMed ID: 30701029
[TBL] [Abstract][Full Text] [Related]
39. CK2α is essential for embryonic morphogenesis.
Dominguez I; Degano IR; Chea K; Cha J; Toselli P; Seldin DC
Mol Cell Biochem; 2011 Oct; 356(1-2):209-16. PubMed ID: 21761203
[TBL] [Abstract][Full Text] [Related]
40. Multiple myeloma cell survival relies on high activity of protein kinase CK2.
Piazza FA; Ruzzene M; Gurrieri C; Montini B; Bonanni L; Chioetto G; Di Maira G; Barbon F; Cabrelle A; Zambello R; Adami F; Trentin L; Pinna LA; Semenzato G
Blood; 2006 Sep; 108(5):1698-707. PubMed ID: 16684960
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
